secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210615
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk Therapeutics Q1 net loss $22.2M; cash $123M funds into 2028
---------------------------------------------------------------------

- Net loss of $22.2M for Q1 2026 vs net income of $73.0M in Q1 2025, which included an $87.4M gain on sale of Aadi Subsidiary.
- Cash, cash equivalents and short-term investments of $123.0M as of March 31, 2026, down from $145.7M at Dec 31, 2025; expected to fund operations into 2028.
- R&D expenses of $17.2M, including $5.3M development milestone to WuXi Biologics, up from $8.8M in Q1 2025.
- Phase 1 trials for HWK-007 and HWK-016 continue enrollment; IND for HWK-206 in small-cell lung cancer/neuroendocrine tumors on track for mid-2026.
- Initial Phase 1 data for pipeline candidates expected in the first half of 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526210615/0001193125-26-210615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312526210615/whwk-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer